Vivani Medical Mergers and Acquisitions Presentation Deck

6-Month NPM-119 Preclinical Proof-of-Concept Achieved Exenatide Plasma Concentration Normalized to 250g Rats (ng/mL) 16 N 30 →-6-Month NPM-119 Prototype (n=6) 60 90 120 Time from initial initiation (days) Implants removed. 150 * Exenatide antibody-positive animals are not included in this data set. **2 of 6 implants are responsible for higher Day 1 exenatide concentrations. Additional optimization ongoing to yield consistent gradual initial PX profiles. 700 600 500 400 300 200 100 Concentration in Plasma 85 kg Human (pg/mL) Exenatide EC 50 17

View entire presentation